Clinical trials: Glaucoma Secondary
Glaucoma,Open-Angle, Ocular Hypertension
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®
The primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months. The secondary objective is to study the other efficacy parameters during treatment for 3 months
- Trial name
- NCT00486252
- Testing
- Observational
- Volunteers
- 996 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.